Literature DB >> 21907408

Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.

M T Voso, L Fianchi, M Criscuolo, M Greco, F D'Alo, S Hohaus, L Pagano, G Leone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21907408     DOI： 10.1016/j.leukres.2011.08.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  1 in total

1.  Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.

Authors:  Andrea Tendas; Maria Felicita Lissia; Daniela Piccioni; Liliana Tirimbelli; Laura Scaramucci; Marco Giovannini; Teresa Dentamaro; Alessio Perrotti; Paolo de Fabritiis; Pasquale Niscola
Journal:  Support Care Cancer       Date:  2014-11-05       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.